Potential in vivo amelioration by N-Acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: Toward therapeutic modulation of mild cognitive impairment

Journal of Neuroscience Research

Volumn 88, Issue 12, 2010, Pages 2618-2629

  Huang, Quanzhen ^a,b   Aluise, Christopher D ^a,b   Joshi, Gururaj ^a,b   Sultana, Rukhsana ^a   St Clair, Daret K ^a   Markesbery, William R ^b   Butterfield, D Allan ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

APP PS 1; Glutathione; Lipid peroxidation; N acetyl cysteine; Oxidative stress; Protein oxidation

Indexed keywords

3 NITROTYROSINE; 4 HYDROXYNONENAL; ACETYLCYSTEINE; AMYLOID BETA PROTEIN; ANTIOXIDANT; CARBONYL DERIVATIVE; DRINKING WATER; FREE RADICAL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; PEPTIDYLPROLYL ISOMERASE PIN1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN TISSUE; COGNITIVE DEFECT; CONTROL GROUP; CONTROLLED STUDY; ENZYME ACTIVITY; IN VIVO STUDY; KNOCKOUT MOUSE; LIPID PEROXIDATION; MALE; MOUSE; MOUSE STRAIN; MUTANT; MUTATION; NEUROPROTECTION; NITRATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GENE KNOCK-IN TECHNIQUES; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUTATION; OXIDATIVE STRESS; PRESENILIN-1; TIME FACTORS;

EID: 77955485786     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22422     Document Type: Article

References (76)

1. Abdul HM, Sultana R, St. Clair DK, Markesbery WR, Butterfield DA. 2008. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic Biol Med 45:1420-1425.
2. Anantharaman M, Tangpong J, Keller JN, Murphy MP, Markesbery WR, Kiningham KK, St. Clair DK. 2006. Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am J Pathol 168:1608-1618.
3. Anderson ME, Luo JL. 1998. Glutathione therapy: from prodrugs to genes. Semin Liver Dis 18:415-424.
4. Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. 2000. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 11:2491-2493. (Pubitemid 30622295)
5. Ansari MA, Joshi G, Huang Q, Opii WO, Abdul HM, Sultana R, Butterfield DA. 2006. In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: relevance to Alzheimer's disease and other oxidative stress-related neurodegenerative disorders. Free Radic Biol Med 41:1694-1703.
6. Beckman KB, Ames BN. 1998. The free radical theory of aging matures. Physiol Rev 78:547-581.
7. Behl C. 2002. Neuroprotective strategies in Alzheimer's disease. Adv Exp Med Biol 513:475-496.
8. Benzi G, Moretti A. 1995. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging 16:661-674.
9. Bolanos JP, Cidad P, Garcia-Nogales P, Delgado-Esteban M, Fernandez E, Almeida A. 2004. Regulation of glucose metabolism by nitrosative stress in neural cells. Mol Aspects Med 25:61-73.
10. Bolanos JP, Delgado-Esteban M, Herrero-Mendez A, Fernandez-Fernandez S, Almeida A. 2008. Regulation of glycolysis and pentose-phosphate pathway by nitric oxide: impact on neuronal survival. Biochim Biophys Acta 1777:789-793.
11. Boothby LA, Doering PL. 2005. Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother 39:2073-2080.
12. Borchelt DR, Thinakaran G, Eckman CB, et al. 1996. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17:1005-1013.
13. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. 1997. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939-945.
14. Bosetti F, Brizzi F, Barogi S, Mancuso M, Siciliano G, Tendi EA, Murri L, Rapoport SI, Solaini G. 2002. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging 23:371-376.
15. Boyd-Kimball D, Sultana R, Poon HF, Mohmmad-Abdul H, Lynn BC, Klein JB, Butterfield DA. 2005. Gamma-glutamylcysteine ethyl ester protection of proteins from Abeta(1-42)-mediated oxidative stress in neuronal cell culture: a proteomics approach. J Neurosci Res 79:707-713. (Pubitemid 40476450)
16. Butterfield DAP. 2002. Elevated gutathione as a therapeutic strategy in Alzheimer's disease. Drug Dev Res 56:428-437. (Pubitemid 35168319)
17. Butterfield DA, Lauderback CM. 2002. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32:1050-1060.
18. Butterfield D, Stadtman ER. 1997. Protein oxidation processes in aging brain. Adv Cell Aging Gerontol 2:161-191.
19. Butterfield DA, Drake J, Pocernich C, Castegna A. 2001. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7:548-554.
20. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V. 2002. Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr Biochem 13:444.
21. Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB, Martins RN. 2006a. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J Alzheimers Dis 10:391-397.
22. Butterfield DA, Poon HF, St. Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR. 2006b. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22: 223-232.
23. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, Sultana R. 2006c. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 397:170-173.
24. Butterfield DA, Reed T, Newman SF, Sultana R. 2007a. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 43:658-677. (Pubitemid 47102132)
25. Butterfield DA, Reed TT, Perluigi M, De Marco C, Coccia R, Keller JN, Markesbery WR, Sultana R. 2007b. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 1148:243-248.
26. Carlberg I, Mannervik B. 1985. Glutathione reductase. Methods Enzymol 113:484-490.
27. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. 2002a. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33:562-571.
28. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. 2002b. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase- related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82:1524-1532.
29. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. 2003. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85:1394-1401. (Pubitemid 36702552)
30. Dringen R, Hamprecht B. 1999. N-acetylcysteine, but not methionine or 2-oxothiazolidine-4-carboxylate, serves as cysteine donor for the synthesis of glutathione in cultured neurons derived from embryonal rat brain. Neurosci Lett 259:79-82. (Pubitemid 29064134)
31. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, Morley JE. 2003. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 84:1173-1183. (Pubitemid 36330669)
32. Fontaine MA, Geddes JW, Banks A, Butterfield DA. 2000. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J Neurochem 75:1709-1715.
33. Grundman M, Delaney P. 2002. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 61:191-202.
34. Halliwell B. 2001. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18:685-716.
35. Hansen JM, Go YM, Jones DP. 2005. Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling. Annu Rev Pharmacol Toxicol 45:1-25.
36. Hensley K, Hall N, Subramaniam R, et al. 1995. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65:2146-2156.
37. Katzman R, Saitoh T. 1991. Advances in Alzheimer's disease. FASEB J 5:278-286.
38. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. 2005. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64:1152-1156.
39. Koppal T, Drake J, Butterfield DA. 1999. In vivo modulation of rodent glutathione and its role in peroxynitrite-induced neocortical synaptosomal membrane protein damage. Biochim Biophys Acta 1453:407-411.
40. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. 2001. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem 78:413-416.
41. Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, Zhou Y, Neve R, Ahlijanian MK, Tsai LH. 2003. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 163:83-95.
42. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. 1995. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45:1594-1601.
43. Lovell MA, Gabbita SP, Markesbery WR. 1999. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 72:771-776.
44. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML. 1998. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 150:40-44. (Pubitemid 28146421)
45. Markesbery WR. 1997. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23:134-147.
46. Markesbery WR, Lovell MA. 1998. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19:33-36. (Pubitemid 28167792)
47. Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, Beal MF. 1993. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 34:609-616.
48. Mohmmad Abdul H, Sultana R, Keller JN, St. Clair DK, Markesbery WR, Butterfield DA. 2006. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. J Neurochem 96:1322-1335.
49. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA. 1999. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19:1959-1964. (Pubitemid 29133374)
50. Pahan K, Sheikh FG, Namboodiri AM, Singh I. 1998. N-acetyl cysteine inhibits induction of no production by endotoxin or cytokine stimulated rat peritoneal macrophages, C6 glial cells and astrocytes. Free Radic Biol Med 24:39-48.
51. Pastorino L, Sun A, Lu PJ, et al. 2006. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440:528-534.
52. Perluigi MSR, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, Butterfield DA. 2009. Redox proteomics identification of HNE-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteom Clin Appl 3:682-693.
53. Petersen RC, Thomas RG, Grundman M, et al. 2005. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352:2379-2388.
54. Pocernich CB, La Fontaine M, Butterfield DA. 2000. In-vivo glutathione elevation protects against hydroxyl free radical-induced protein oxidation in rat brain. Neurochem Int 36:185-191. (Pubitemid 30047009)
55. Pocernich CB, Cardin AL, Racine CL, Lauderback CM, Butterfield DA. 2001. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem Int 39:141-149.
56. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. 1977. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 2:432-434.
57. Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, Siman R, Scott RW. 1996. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. J Biol Chem 271:23380-23388. (Pubitemid 26314785)
58. Reed TT, Pierce WM, Turner DM, Markesbery WR, Butterfield DA. 2009. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol Med 13:2019-2029.
59. Sano M, Ernesto C, Thomas RG, et al. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336:1216-1222.
60. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 1997. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68:2092-2097.
61. Sies H. 1999. Glutathione and its role in cellular functions. Free Radic Biol Med 27:916-921.
62. Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, Scott RW, Flood DG. 2000. Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci 20:8717-8726.
63. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. 1997. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17:2653-2657. (Pubitemid 27154998)
64. Stadtman ER, Berlett BS. 1997. Reactive oxygen-mediated protein oxidation in aging and disease. Chem Res Toxicol 10:485-494.
65. Sultana R, Boyd-Kimball D, Poon HF, et al. 2006a. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol Aging 27:918-925.
66. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA. 2006b. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 22:76-87.
67. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA. 2007a. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11:153-164.
68. Sultana R, Reed T, Perluigi M, Coccia R, Pierce WM, Butterfield DA. 2007b. Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study. J Cell Mol Med 11:839-851. (Pubitemid 47313301)
69. Sultana R, Piroddi M, Galli F, Butterfield DA. 2008. Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33:2540-2546.
70. van Groen T, Kiliaan AJ, Kadish I. 2006. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis 23:653-662.
71. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. 2000. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130:184-208.
72. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. 2005. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93:953-962. (Pubitemid 40695754)
73. Wheeler CR, Salzman JA, Elsayed NM, Omaye ST, Korte DW Jr. 1990. Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. Anal Biochem 184:193-199.
74. Yan CY, Greene LA. 1998. Prevention of PC12 cell death by N-acetylcysteine requires activation of the Ras pathway. J Neurosci 18:4042-4049.
75. Zafarullah M, Li WQ, Sylvester J, Ahmad M. 2003. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60:6-20.
76. Zhang Q, Tian H, Fu X, Zhang G. 2003. Delayed activation and regulation of MKK7 in hippocampal CA1 region following global cerebral ischemia in rats. Life Sci 74:37-45.